Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.

The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th. Registration will begin on Monday at 7:00AM and will last until the evening. These days will be jam-packed with company presentations, 1-on-1 meetings, round tables, expert panel discussions, and plenty of time to network with other investors over food and drinks.

REGISTRATION FOR INVESTORS

To request free registration, please go to our website (www.microcapconf.com), and click the “Registration” button

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (www.microcapconf.com)

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu, CEO at [email protected]

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

Investor Contact:

Brett Maas
Hayden IR
(646) 536-7331

[email protected]

James Carbonara
Hayden IR
(646)-755-7412

[email protected]haydenir.com